Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Sunday 05 December 2021 1:42 pm  |  Updated:  Sunday 05 December 2021 1:44 pm

Pfizer accused of funding anti-AstraZeneca information

By: Amy O'Brien

Add as a preferred source on Google
Pfizer CEO Albert Bourla talks during a press conference after a visit at Pfizer vaccine plant in Puurs, Belgium, April 23, 2021. (John Thys /Pool via REUTERS/File Photo)

US drugmaker Pfizer, the world’s dominant Covid vaccine maker, has been accused of funding educational presentations that said its UK rival AstraZeneca was ineffective and even dangerous for some members of the population.

A Channel 4 Dispatches investigation due to be broadcast this week says it has “uncovered evidence” that Pfizer funded a number of educational presentations that were delivered to health professionals across Canada about its mRNA vaccine.

Included in these presentations were slides that listed several disadvantages of the “viral vector” technology that is the basis for the AstraZeneca vaccine, the broadcaster said.

Delivered by speakers who had received funds from Pfizer, the slides said there is a risk of “chromosomal integration and oncogenesis” with such vaccines, which suggests they might turn a healthy cell into a cancerous cell. They also claimed that the AstraZeneca vaccine cannot be used in immunocompromised people.

The claims made about the viral vector vaccine’s disadvatanges originated from a scientific paper written by a group of authors, one of whom had worked for several years in Pfizer’s vaccine division.

Channel 4 Dispatches did not say where it had found the evidence for these claims, and Pfizer denied it “sought to undermine others’ scientific endeavours” .

Professor Sir Andrew Pollard, the director of the Oxford vaccine group that developed the Astra Zeneca vaccine, dismissed the contents of the slides and warned of the dangers of spreading misinformation.

“That would that the vaccine could somehow integrate itself into the genetic material in people, which is not true,” Pollard said.

Read more

Regulator wins decade-long pricing tussle with Pfizer

Hikma reported a jump in profit for 2024

He said there was “absolutely zero evidence” that the vaccine “would or could” cause cancer, and that it had been given to millions of immunocompromised people and caused on harm.

“There is huge risks of misinformation, because anything that makes people hesitate about being vaccinated can risk their lives,” Pollard warned.

“It can undermine and impact on decisions that people make about their own health, but also create uncertainty for policymakers.”

Pfizer said it “provided funds to a third party agency” for an “education programme” but did “not provide presentation materials … and did not edit or influence the presentations”.

In the same investigation, Channel 4 also reveals an analysis by one biological engineering expert that claims the manufacturing costs of Pfizer’s vaccine stands at just 76p per shot, but it is reportedly being sold for £22 a dose to the UK government.

It’s been an extremely lucrative year for the drugmaker, which now wields considerable political influence due to its hefty contracts with governments around the world.

Pfizer forecast sales of its vaccine will hit $36bn in 2021 – double that of its closest rival Moderna. As of October, the pharma group provided 80 per cent of Covid Vaccines in the EU, and 74 per cent in the US.

Read more

NIKE, Inc. Announces Planned CFO Transition

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • AstraZeneca
  • Vaccine

Trending Articles

  • Top Burnham adviser calls for capital gains and inheritance tax hikes

  • A meeting with the breakfast king of Mayfair

  • Clarkson’s Farm and why businesses must stop blaming the weather

  • BT tops FTSE 100 after finding new home for international business with Verizon joint venture

  • FTSE 100 Live: Stocks jump on defence and metals boost; Oil on track to shed a fifth on US-Iran peace hopes

More from City PM

  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • NIKE, Inc. Announces Planned CFO Transition

    Business Wire
  • LivaNova Appoints Anne Liddy as Chief Legal Officer

    Business Wire
  • WorkBoard Extends its Strategy Execution Platform with new AI-Native Strategic Portfolio Management Solution and Portfolio Analyst Agents

    Business Wire
  • Alphabet to join Dow Jones in rare index reshuffle

    Tech
    Googles modern Kings Cross headquarters showcasing innovative architecture in Londons dynamic tech district
  • LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

    Business Wire
  • IGI President & CEO Waleed Jabsheh to Present at the 16th Annual East Coast IDEAS Investor Conference on June 10, 2026 in New York City

    Business Wire
  • Wise profit slides as costs racks up from US listing

    Fintech
    Wise outlined plans to shift its primary listing to the US in June.

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy